Study S000109

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia - A Single-arm, Non-interventional Retrospective Chart Review Study

ClinicalTrials.gov record

Registration

Registration: NCT05324462
Acronym: SPIRIT
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 175
Start: 2022-03-22
Primary completion: 2022-07-15
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:IDegLira
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1266-5484

Registered primary outcomes

Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c) [From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004216	SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia. Ramírez-Rincón A, Diabetes therapy : research, treatment and education of diabetes and related disorders	2024	Nonrandomized study	PMID 38717577 DOI	cites ClinicalTrials.gov:NCT05324462; registry reference DERIVED:38717577
R0012853	SPIRIT – Assessing clinical parameters associated with using IDegLira in patients with Type 2 Diabetes in a real-world setting in Colombia: a single arm, retrospective, chart review study Ramírez A, Research Square	2023	Nonrandomized study	DOI	cites ClinicalTrials.gov:NCT05324462